Tag: Dr. Pablo J. Cagnoni
Rubius to lay off about 70 R.I. employees, considering sale of...
SMITHFIELD – Rubius Therapeutics plans to lay off 75% of its workforce, including about 70 of its 101 employees in Rhode Island, and is...
Rubius Therapeutics reports $196.5M loss in 2021
PROVIDENCE – Rubius Therapeutics Inc. on Friday reported a loss of $196.5 million in 2021, or $2.23 per diluted share.
The clinical-stage biopharmaceutical company, which...
Rubius Therapeutics posts $42.3M loss in Q1
CAMBRIDGE, Mass. – Rubius Therapeutics Inc. reported a $42.3 million loss in the first quarter of 2021, or 51 cents per diluted share, the...
Rubius Therapeutics reports $167.7M loss in 2020
CAMBRIDGE, Mass. – Rubius Therapeutics Inc. reported Tuesday a loss of $167.7 million in 2020, or $2.08 per diluted share.
The clinical-stage biopharmaceutical company, which...
Rubius announces 3 new patents for cellular-therapy program
PROVIDENCE – Rubius Therapeutics, a Cambridge, Mass.-based biotech firm that develops and genetically engineers red blood cells for use in medications for rare diseases,...
Rubius appoints Holles to board, Whitehead as SVP, chief quality officer
PROVIDENCE – Rubius Therapeutics Inc. has appointed Natalie Holles to its board of directors and Greg Whitehead as senior vice president and chief quality...
- Featured Event -
